The LIFR Inhibitor EC359 Effectively Targets Type II Endometrial Cancer by Blocking LIF/LIFR Oncogenic Signaling

Author:

Spencer Nicole1,Rodriguez Sanchez Alondra Lee1,Gopalam Rahul1,Subbarayalu Panneerdoss2,Medina Daisy M.2ORCID,Yang Xue1ORCID,Ramirez Paulina1,Randolph Lois1,Aller Emily Jean1,Santhamma Bindu3,Rao Manjeet K.2,Tekmal Rajeshwar Rao1,Nair Hareesh B.3,Kost Edward R.1,Vadlamudi Ratna K.145ORCID,Viswanadhapalli Suryavathi14ORCID

Affiliation:

1. Division of Reproductive Research, Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA

2. Department of Cell Systems & Anatomy, Greehey Children’s Cancer Research Institute, University of Texas Health San Antonio, San Antonio, TX 78229, USA

3. Evestra, Inc., San Antonio, TX 78245, USA

4. Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA

5. Audie L. Murphy Division, South Texas Veterans Health Care System, San Antonio, TX 78229, USA

Abstract

Endometrial cancer (ECa) is the most common female gynecologic cancer. When comparing the two histological subtypes of endometrial cancer, Type II tumors are biologically more aggressive and have a worse prognosis than Type I tumors. Current treatments for Type II tumors are ineffective, and new targeted therapies are urgently needed. LIFR and its ligand, LIF, have been shown to play a critical role in the progression of multiple solid cancers and therapy resistance. The role of LIF/LIFR in the progression of Type II ECa, on the other hand, is unknown. We investigated the role of LIF/LIFR signaling in Type II ECa and tested the efficacy of EC359, a novel small-molecule LIFR inhibitor, against Type II ECa. The analysis of tumor databases has uncovered a correlation between diminished survival rates and increased expression of leukemia inhibitory factor (LIF), suggesting a potential connection between altered LIF expression and unfavorable overall survival in Type II ECa. The results obtained from cell viability and colony formation assays demonstrated a significant decrease in the growth of Type II ECa LIFR knockdown cells in comparison to vector control cells. Furthermore, in both primary and established Type II ECa cells, pharmacological inhibition of the LIF/LIFR axis with EC359 markedly decreased cell viability, long-term cell survival, and invasion, and promoted apoptosis. Additionally, EC359 treatment reduced the activation of pathways driven by LIF/LIFR, such as AKT, mTOR, and STAT3. Tumor progression was markedly inhibited by EC359 treatment in two different patient-derived xenograft models in vivo and patient-derived organoids ex vivo. Collectively, these results suggest LIFR inhibitor EC359 as a possible new small-molecule therapeutics for the management of Type II ECa.

Funder

NIH

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Reference35 articles.

1. Endometrial Cancer: Is This a New Disease?;Moore;Am. Soc. Clin. Oncol. Educ. Book.,2017

2. High-Grade Endometrial Cancer-Behaviour and Outcomes at a Tertiary Cancer Centre;Lakhwani;Indian. J. Surg. Oncol.,2019

3. Clinical actionability of molecular targets in endometrial cancer;Urick;Nat. Rev. Cancer,2019

4. Overall survival and disease-free survival in endometrial cancer: Prognostic factors in 276 patients;Onco Targets Ther.,2013

5. Endometrial Cancer: Obesity, Genetics, and Targeted Agents;McDonald;Obstet. Gynecol. Clin. N. Am.,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3